Literature DB >> 9415944

HLA haplotypes, polysomnography, and pedigrees in a case series of patients with narcolepsy.

R Hayduk1, P Flodman, M A Spence, M K Erman, M M Mitler.   

Abstract

An ongoing study of the genetics of narcolepsy ascertains families through a case series of narcoleptic probands using diagnostic criteria consisting of 1) clinical history of excessive somnolence, 2) a mean sleep latency on the multiple sleep latency test (MSLT) of less than 7.9 minutes, 3) the rapid eye movement (REM) sleep-related symptom of cataplexy, 4) nocturnal polysomnography ruling out sleep apnea syndrome, and 5) two or more transitions to REM sleep on the MSLT. All probands and first-degree relatives received clinical and laboratory evaluations as well as human leukocyte antigen (HLA) typing. Demographic characteristics of the 32 probands are as follows: 17 males and 15 females; mean age was 42.1 years (range 13-70 years). The polysomnographic data confirmed daytime sleepiness and increased tendency for REM sleep for the 32 probands. Nocturnal polysomnographic results are as follows: sleep latency, 3.2 minutes; total sleep time, 442 minutes. MSLT results are as follows: sleep latency, 3.1 minutes; REM latency, 6.9 minutes; number of REM periods, 3.2. HLA typing revealed the presence of the HLA haplotypes, DRB1*15 and DQB1*0602, in 21 narcoleptic probands, with two African-Americans having the DQB1*0602 but not the DRB1*15 allele. Among the 57 relatives of the 32 probands, 1/31 females and 7/26 males were found to be affected with narcolepsy (p < 0.02), which suggests a higher diagnostic rate in male relatives. The 21 probands who were positive for the DRB1*15 and DQB1*0602 haplotypes did not differ from the 10 probands who were negative for these alleles in terms of their nocturnal sleep parameters, MSLT findings, or clinical presentation. Three families with multiple individuals affected with narcolepsy are presented. Two families have more than one affected individual who does not have the high-risk HLA haplotype. In one of these families, the disease is segregating independently of any HLA haplotype. In the third family, there is cosegregation with HLA DRB1*15 and DQB1*0602. One family contains a pair of DNA-confirmed, monozygotic twins with narcolepsy who are discordant for cataplexy and have the HLA DR14(Dw9)/DQB1*0503 and DR4(Dw4)/DQB1*0302 haplotypes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9415944      PMCID: PMC2248798          DOI: 10.1093/sleep/20.10.850

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  15 in total

1.  Diagnosis of twin zygosity by hypervariable RFLP markers.

Authors:  A Akane; K Matsubara; H Shiono; M Yamada; Y Nakagome
Journal:  Am J Med Genet       Date:  1991-10-01

2.  Nomenclature for factors of the HLA system, update May 1996. WHO Nomenclature Committee for Factors of the HLA system.

Authors:  S G Marsh
Journal:  Tissue Antigens       Date:  1996-08

3.  Nomenclature for factors of the HLA system, update June 1996.

Authors:  S G Marsh
Journal:  Tissue Antigens       Date:  1996-09

4.  HLA-DR2 and narcolepsy: not all narcoleptic-cataplectic patients are DR2.

Authors:  C Guilleminault; C Grumet
Journal:  Hum Immunol       Date:  1986-09       Impact factor: 2.850

5.  Extraordinary association between HLA-DR2 and narcolepsy.

Authors: 
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

6.  HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive.

Authors:  T Juji; M Satake; Y Honda; Y Doi
Journal:  Tissue Antigens       Date:  1984-11

7.  HLA-DR2 association with excessive somnolence in narcolepsy does not generalize to sleep apnea and is not accompanied by systemic autoimmune abnormalities.

Authors:  R L Rubin; R M Hajdukovich; M M Mitler
Journal:  Clin Immunol Immunopathol       Date:  1988-10

8.  HLA antigens in narcolepsy and idiopathic central nervous system hypersomnolence.

Authors:  G Poirier; J Montplaisir; F Décary; D Momège; A Lebrun
Journal:  Sleep       Date:  1986       Impact factor: 5.849

9.  Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline.

Authors:  M M Mitler; R Shafor; R Hajdukovich; R M Timms; C P Browman
Journal:  Sleep       Date:  1986       Impact factor: 5.849

10.  HLA and narcolepsy in a German population.

Authors:  G Mueller-Eckhardt; K Meier-Ewert; D J Schendel; F B Reinecker; G Multhoff; C Mueller-Eckhardt
Journal:  Tissue Antigens       Date:  1986-09
View more
  7 in total

Review 1.  Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up.

Authors:  C Guilleminault; R Pelayo
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  Benefits and risks of pharmacotherapy for narcolepsy.

Authors:  Merrill M Mitler; Roza Hayduk
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  From wakefulness to excessive sleepiness: what we know and still need to know.

Authors:  Maurice Moyses Ohayon
Journal:  Sleep Med Rev       Date:  2008-04       Impact factor: 11.609

4.  The impact of gender on timeliness of narcolepsy diagnosis.

Authors:  Christine Won; Mandana Mahmoudi; Li Qin; Taylor Purvis; Aditi Mathur; Vahid Mohsenin
Journal:  J Clin Sleep Med       Date:  2014-01-15       Impact factor: 4.062

5.  The familial risk and HLA susceptibility among narcolepsy patients in Hong Kong Chinese.

Authors:  Lei Chen; S Y Y Fong; Ching W Lam; Nelson L S Tang; Margaret H L Ng; Albert M Li; C K W Ho; Suk-Hang Cheng; Kin-Mang Lau; Yun Kwok Wing
Journal:  Sleep       Date:  2007-07       Impact factor: 5.849

Review 6.  A practical approach to the diagnosis and management of sleep disorders in patients with multiple sclerosis.

Authors:  Tiffany J Braley; Ronald D Chervin
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

Review 7.  A review on genetics of sleep disorders.

Authors:  Reza Bidaki; Mina Zarei; Ali Khorram Toosi; Mitra Hakim Shooshtari
Journal:  Iran J Psychiatry Behav Sci       Date:  2012
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.